{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:42:48Z","timestamp":1785321768320,"version":"3.55.0"},"reference-count":74,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,10,27]],"date-time":"2012-10-27T00:00:00Z","timestamp":1351296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the effects of oral nonsteroidal antiinflammatory drugs (NSAIDs) on C\u2010reactive protein (CRP) levels in rheumatoid arthritis (RA) patients, with a prespecified focus on the different NSAIDs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a systematic search in Medline via PubMed, the Cochrane Central Register of Controlled Trials, EMBase via OVID, the Institute for Scientific Information Web of Science, and other sources. Eligible trials were parallel\u2010group, randomized, placebo\u2010controlled trials of oral NSAID therapy in RA patients for which there were extractable CRP data. Standardized mean differences (SMDs) with 95% confidence intervals (95% CIs) were calculated from the differences in means of CRP levels between groups (active treatment minus placebo) divided by the pooled SDs. For the meta\u2010analysis, a random\u2010effects model was used to estimate the overall change in CRP level, and stratified analysis was used to examine differences among NSAIDs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 19 trials of 10 different NSAIDs. Overall, NSAIDs showed no effect on the CRP level (SMD 0.01 [95% CI \u22120.03, 0.06], <jats:italic>P<\/jats:italic> = 0.62). However, the prespecified stratified analysis indicated varying effects on the CRP level according to the different NSAIDs; lumiracoxib caused a statistically significant and consistent (I<jats:sup>2<\/jats:sup> = 0%) increase in the CRP level (SMD 0.13 [95% CI 0.01, 0.25], <jats:italic>P<\/jats:italic> = 0.037), whereas naproxen caused a statistically significant and consistent (I<jats:sup>2<\/jats:sup> = 0%) decrease in the CRP level (SMD \u22120.11 [95% CI \u22120.20, \u22120.02], <jats:italic>P<\/jats:italic> = 0.022).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Overall, NSAIDs have no effect on the CRP level. However, the nonselective NSAID naproxen was associated with a significant decrease in the CRP level, whereas the cyclooxygenase 2\u2013selective NSAID lumiracoxib was associated with a significant increase in the CRP level. This finding is interesting considering the suspected influence of NSAIDs on cardiovascular complications.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.34644","type":"journal-article","created":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T15:37:51Z","timestamp":1343230671000},"page":"3511-3521","source":"Crossref","is-referenced-by-count":46,"title":["Effect of nonsteroidal antiinflammatory drugs on the C\u2010reactive protein level in rheumatoid arthritis: A meta\u2010analysis of randomized controlled trials"],"prefix":"10.1002","volume":"64","author":[{"given":"Simon","family":"Tarp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else M.","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Bliddal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Furst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Boers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Danneskiold\u2010Sams\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,10,27]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta12110"},{"key":"e_1_2_8_3_2","first-page":"41","article-title":"A better understanding of anti\u2010inflammatory drugs based on isoforms of cyclooxygenase (COX\u20101 and COX\u20102)","volume":"23","author":"Vane JR","year":"1995","journal-title":"Adv Prostaglandin Thromboxane Leukot Res"},{"key":"e_1_2_8_4_2","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. ATC\/DDD index2011. URL:http:\/\/www.whocc.no\/atcddd\/."},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7504.1366"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7553.1302"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c7086"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17514-4"},{"key":"e_1_2_8_9_2","unstructured":"US Food and Drug Administration. COX\u20102 selective (includes Bextra Celebrex and Vioxx) and non\u2010selective non\u2010steroidal anti\u2010inflammatory drugs (NSAIDs). URL:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm103420.htm."},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1740"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24123"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61717-7"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21204"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2006.00033.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330103"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330504"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/32.suppl_3.14"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(05)80003-4"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.49.11.916"},{"key":"e_1_2_8_21_2","volume-title":"Cochrane handbook for systematic reviews of interventions, version 5.1.0","author":"Higgins JP","year":"2011"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00136"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/31.1.140"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.08.017"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39465.451748.AD"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq336"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61721-8"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_8_32_2","unstructured":"Thomson Reuters\/Truven Health Analytics. Micromedex 1.0.2011. URL:http:\/\/www.micromedex.com\/products\/."},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1187"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0645rev"},{"key":"e_1_2_8_35_2","first-page":"721","article-title":"Analysis of elevated serum interleukin\u20106 levels in rheumatoid arthritis: correlation with erythrocyte sedimentation rate or C\u2010reactive protein","volume":"123","author":"Cohick CB","year":"1994","journal-title":"J Lab Clin Med"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007997509114780"},{"key":"e_1_2_8_37_2","first-page":"1382","article-title":"Double blind and dosage studies on tolectine in rheumatoid arthritis","volume":"51","author":"Bachmann F","year":"1975","journal-title":"Z Allgemeinmed"},{"key":"e_1_2_8_38_2","first-page":"26","article-title":"Comparative effectiveness of Voltaren and indomethacin in rheumatoid arthritis (according to the data of a double\u2010blind study)","volume":"50","author":"Tsvetkova ES","year":"1978","journal-title":"Ter Arkh"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/32.suppl_3.19"},{"key":"e_1_2_8_41_2","first-page":"282","article-title":"Efficacy and safety of meloxicam in patients with rheumatoid arthritis","volume":"24","author":"Lemmel EM","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.20.1921"},{"key":"e_1_2_8_43_2","first-page":"436","article-title":"Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac","volume":"29","author":"Furst DE","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-3-10"},{"key":"e_1_2_8_45_2","first-page":"1623","article-title":"A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis","volume":"29","author":"Matsumoto AK","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.06.016"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740701286771"},{"key":"e_1_2_8_48_2","first-page":"891","article-title":"Clinical evaluation of TS\u2010110 against rheumatoid arthritis: dose finding study using placebo","volume":"13","author":"Mizushima Y","year":"1997","journal-title":"Rinsho Iyaku"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1080\/030097402320318431"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.01.016"},{"key":"e_1_2_8_51_2","unstructured":"GD Searle. Valdecoxib NDA 21\u2010341. Statistical review(s) part IV: Tables 46 and 53 results for secondary endpoints (protocols 060 and 061).2002; p. 60 64\u20135. URL:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/21\u2010341_Bextra_statr_P1.pdf."},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2004.00398.x"},{"key":"e_1_2_8_53_2","unstructured":"Medicines and Healthcare Products Regulatory Agency. UK public assessment report for Prexige 100mg tablets (Lumiracoxib) PL 00101\/0677.2007. URL:http:\/\/www.mhra.gov.uk\/home\/groups\/l\u2010unit1\/documents\/websiteresources\/con2032604.pdf."},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(99)80048-4"},{"key":"e_1_2_8_55_2","unstructured":"GlaxoSmithKline. COX\u20102 inhibitor study in patients with rheumatoid arthritis. ClinicalTrials.gov identifier: NCT00113308. A phase III 12\u2010week multicentre double\u2010blind randomised placebo\u2010 and active comparator\u2010controlled parallel group study to investigate the efficacy and safety of GW406381 5mg 10mg 25mg and 50mg administered orally once daily in adults with rheumatoid arthritis. URL:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00113308?term=GW406381&rank=4."},{"key":"e_1_2_8_56_2","first-page":"280","article-title":"Efficacy and tolerability of lumiracoxib in the treatment of rheumatoid arthritis: a 13\u2010week, randomized, double\u2010blind study","volume":"63","author":"Pavelka K","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X20231"},{"key":"e_1_2_8_58_2","first-page":"S369","article-title":"Results of a pivotal (phase III) placebo and active comparator controlled efficacy trial of rofecoxib 12.5 and 25 mg in adult patients with rheumatoid arthritis (RA)","volume":"44","author":"Truitt K","year":"2001","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_59_2","doi-asserted-by":"crossref","unstructured":"CurtisSP Maldonado\u2010CoccoJ LosadaBR GallagherAE NgJ MukhopadhyayS et al.Treatment with etoricoxib (MK\u20100663) a COX\u20102 selective inhibitor resulted in maintenance of clinical improvement in rheumatoid arthritis[abstract]. European League Against Rheumatism: Abstracts from the 2001 Annual Congress Prague Czech Republic June 13\u201316 2001.","DOI":"10.1136\/annrheumdis-2001.1159"},{"key":"e_1_2_8_60_2","unstructured":"Novartis. A 13 week multicenter randomized double\u2010blind double\u2010dummy placebo\u2010controlled parallel group trial of two doses of lumiracoxib (200 and 400 mg qd) in patients with rheumatoid arthritis using celecoxib (200 mg bid) as a comparator. CCOX189A0114.2009. URL:http:\/\/www.novctrd.com\/ctrdWebApp\/clinicaltrialrepository\/displayFile.do?trialResult=2605."},{"key":"e_1_2_8_61_2","unstructured":"GD Searle. Celecoxib NDA 20\u2010998. Medical review part 12: Table A.41 C\u2010reactive protein (protocol 023).2005; p. 208. URL:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/20998AP_medr_P12.pdf."},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.9.1008"},{"issue":"3","key":"e_1_2_8_63_2","first-page":"2788","article-title":"Title only in Japanese","volume":"26","author":"Abe T","year":"2006","journal-title":"Progress in Medicine"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2008.01.002"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65230-3"},{"key":"e_1_2_8_66_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.8.840"},{"key":"e_1_2_8_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07370-1"},{"key":"e_1_2_8_68_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.240459597"},{"key":"e_1_2_8_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken415"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1409"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2008.525"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60137-3"},{"key":"e_1_2_8_73_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.12.1367"},{"key":"e_1_2_8_74_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c365"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-5174.2007.00002.x"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.34644","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.34644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T02:34:29Z","timestamp":1698719669000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.34644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,27]]},"references-count":74,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1002\/art.34644"],"URL":"https:\/\/doi.org\/10.1002\/art.34644","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,27]]}}}